Régis Vaillancourt

Senior Scientist, CHEO Research Institute

Dr. Régis Vaillancourt currently serves as the director of pharmacy for the Children’s Hospital of Eastern Ontario (CHEO). Spanning over four decades of professional service, Dr. Vaillancourt continues to be active in Canadian pharmacy, underscored by his involvement in the community as a practitioner, his recognized role in research as an academic, and his service as past-president and active member of several pharmacy boards, committees, associations, and federations. For over thirty years Régis has been addressing common issues in the practice of pharmacy in Canada where he has demonstrated his impact in his profession not only nationally with his executive roles with the Canadian Society of Hospital Pharmacy, but also on a global scale with executive roles with the International Pharmaceutical Federation.

Dr. Vaillancourt’s dedication to the pharmacy profession has been recognized locally, nationally and internationally through numerous awards and appointments. In 2004 the Canadian Pharmacists Association named him the Canadian Pharmacist of the Year. In addition to pharmacy related accolades, he was awarded the Order of Military Merit by former Governor General, Adrienne Clarkson. He was awarded the title of Fellow by the Canadian Society of hospital Pharmacy the International Pharmaceutical Federation and the Ordre des pharmaciens du Quebec.

For the last 12 years, Dr. Vaillancourt has worked closely with physicians to develop infographic-based medication calendars, disease management plans and drug instructions for their patients with low health literacy, and is currently leading research on the medical use of cannabis in children and adults.

Research Projects

  1. Cannabis use for therapeutic purposes by children and youth at a tertiary teaching hospital in Canada: A retrospective chart review


    Medically supervised cannabis use occurred most often in patients with intractable or refractory seizures. According to these data, seizure response is variable, and initial decreases may be transient for pediatric patients using cannabis. To ensure greater consistency and rigour in the conduct of prospective research and thus to generate better-quality research on the therapeutic effects of medical cannabis, development of a standardized care record is needed.

  2. Analyses of Adverse Drug Reactions-Nationwide Active Surveillance Network: Canadian Pharmacogenomics Network for Drug Safety Database


    Adverse drug reactions (ADRs) are a major problem in modern medicine, representing up to the fourth‐highest cause of mortality.

  3. Defining and identifying concepts of medication literacy: an international perspective


    Future studies should focus on how this definition can be operationalized to support the role that pharmacists and other healthcare providers.